In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Pragmatic, Single-blind, Randomized Crossover Trial Testing the Effectiveness of Autonomous Remote Patient Peripheral Edema Monitoring and Reporting in HEART FailurE Compared to conventionaL remoTe Patient Monitoring.
About this study
Participants will be recruited through Remote Patient Monitoring Providers (RPMPs) based in the US, using crossover randomization between standard care and Heartfelt device usage with health alerts sent to RPMPs. The RPMPs will follow a protocolized intervention when responding to raised alerts.
The study design is a crossover randomization between:
* Standard care (control), 162 days: The device is installed in the home and captures data but no health alerts are sent, and the RPMP does not receive data from the device. (Health alerts are generated and stored for review at the end of the study period to correlate with health issues which occurred during usual care).
* Standard care + Heartfelt (intervention), 162 days: The device captures data and transmits volume measurements and health alerts to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
At consent, patients get randomized to an install date over a period from 21 to 60 days following consent, subject to scheduling this at least 14 days after the most recent recorded hospital discharge at the time of consent, or the discharge from their current hospitalization if hospitalized at the time of consent.
Total study length is 366 days (days 0 to 365). There are two 21-day "washout" periods to prevent carryover between study arms. The first washout period extends from day 0-20 inclusive, and the second from day 183-203 inclusive
At the completion of both crossover arms, patients will be offered the opportunity to keep the device for as long as the study remains active (potentially up to an additional 4 years, for those patients recruited early in the study). During this long-term follow-up, the device will be placed in "Intervention" mode, with randomized 100-day periods where the device is switched into "Standard care" mode (control).
Eligibility criteria
Inclusion Criteria:
* Provision of signed and dated informed consent form (wet or digital signature)
* Male or female, aged 22 to \[No maximum age\]
* Diagnosed with Chronic Heart failure at least 2 months prior to randomization.
* Exhibited peripheral edema on at least one HF-related hospitalization in the last 4 years (as documented in EHR).
* Has been hospitalized for HF, received IV diuretics treatment or visited the ER for HF decompensation at least once in the last 6 months or twice in the last 12 months.
* Participants who are treated with daily diuretics.
* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of the study.
* Has failed to collect at least 50% of days over the last 180 of physiological data (incl. home weights and/or BP) from monitoring devices OR has been discontinued from remote patient monitoring due to non-adherence, OR, is considered by clinical team as non-adherent but does not have historical physiological data from monitoring devices.
* Patients who are covered by an insurance plan that covers IDE-B costs (e.g. Medicare).
Exclusion Criteria:
* Participant has bandages to lower limbs every day
* Participant has an amputation of both feet
* Participant is a regular wheelchair user inside their home
* Participant is bed-bound
* Participant is of no fixed abode
* Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes
* Participant who was unable to have the device installed and activated within 90 days of the randomized installation date
* Participant is unable to take diuretics
* Participant is on a regular schedule of dialysis
* Participant has a history of recurrent deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
* Participant has a history of recurrent cellulitis episodes (two or more episodes within the last 12 months).
* Participant is prescribed diltiazem or verapamil on an ongoing basis.
* Participant is pregnant or is not taking relevant birth control if of child-bearing potential
Study design
Enrollment target: 1500 participants
Allocation: randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2025-10-23
Estimated completion: 2030-12-31
Last updated: 2025-11-04
Interventions
Device: Heartfelt Device installedOther: Standard careDevice: Heartfelt-guided careOther: Questionnaires
Primary outcomes
- • Heart Failure Events (HFEs, a composite of HFH or Worsening HF event without hospitalization (as defined in [1-Abraham]) (12 months, plus up to 48 months long term follow-up)
- • Doubling in serum creatinine (sCr) from baseline with at least 2.0mg/dL (12 months, plus up to 48 months long term follow-up)
Sponsor
Heartfelt Technologies · industry
Contacts & investigators
ContactWH Wilson Tang, MD · contact · usa.trial@hftech.org · +441223 967250
ContactAmparito Cunningham, MD. MPH. · contact · amparito@hftech.org · 6176425062
InvestigatorWH Wilson Tang, MD · study_chair, Cleveland Clinic, USA
All locations (3)
RimidiNot Yet Recruiting
Atlanta, Georgia, United States
HealthArcNot Yet Recruiting
Hackensack, New Jersey, United States
Connect AmericaRecruiting
Bala-Cynwyd, Pennsylvania, United States